

Short profile

Name: Cardiokol Ltd.



Medical field	Cardiovascular, Arrhythmias
Product type	Digital Health, Atrial Fibrillation detection and monitoring via vocal biomarkers
Growth stage	Post seed, after clinical studies, first product launched
Team	Cardiokol management team has extensive experience in leading both private and public Pharma, MedTech and Telecom companies. Their experience ranges from inception of new technologies to global sales, including initial public offering (IPO) on a public stock exchange, and M&A. Cardiokol team has gain practical & theoretical knowledge in developing voice-based markers and monitoring solutions for heart rhythm disorders, utilizing proprietary technology that is implemented in speech platforms such as phones and smart-speakers. The multidisciplinary experience of the managers and the team includes unique specializations necessary for the implementation of the company's vision. The company is supported by a world renowned cardiology experts and KOLs.

Description of product:

VAAM (Voice-Assist Arrhythmia Monitoring application) is a medical software application service, offering several use cases. The product is based on proprietary AF vocal markers technology that utilizes phones, voice-assistants and other existing speech platforms to support low-cost, long-term, extended monitoring and mass-screening of large populations at risk. The technology utilizes the users voice signals to detect AF, and is based on AF-related chaotic heartbeats that slightly modify the acoustic properties of the laryngeal ("vocal box") arteries, affecting voice production. The voice-analysis algorithm is



Pini@cardiokol.com



+972542008000

DR. HANA HASTOR, Medical Advisor CSC (CRU)
hana.hastor@bih-charite.de

DR. VERENA BENZ, Strategic Cooperations,
Charité BIH Innovations
verena.benz@bih-charite.de



www.cardiokol.com

capable of monitoring patients at risk without the need to wear, operate, or charge special devices, therefore providing a device-less, elderly-friendly solution. Often AF is asymptomatic (up to 90% of the episodes are asymptomatic) thus resulting in low detection rates. Our product capable of detecting both symptomatic & asymptomatic episodes.

Peer-reviewed paper was published at the Journal of Cardiovascular Electrophysiology (JCE) – "Automated detection of atrial fibrillation based on vocal features analysis" -
<https://onlinelibrary.wiley.com/doi/10.1111/jce.15595>

Desired project goal: *Please also elaborate on the primary outcome*

Facilitation of AF clinical studies and regulatory approvals. Potential service agreement with the Charité TMCC. Ability to penetrate the German market.

Desired project type: *Please also elaborate on the following points, if applicable: population, intervention, study design etc.*

The purpose of the study is to demonstrate the effectiveness of the VAAM application in identification of new AF patients and to support the local regulatory approval (DiGA/BfArM) for the VAAM application.
Subject Population:

Cohort A: Male or female aged 75 and above

Cohort B: Male or female aged 65 and above and at least one risk factor.

Sample size: 150 patients.

The study is non invasive.

DR. HANA HASTOR, Medical Advisor CSC (CRU)
hana.hastor@bih-charite.de

DR. VERENA BENZ, Strategic Cooperations,
Charité BIH Innovations
verena.benz@bih-charite.de